A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.

Trial Details

NCT ID
NCT05652686
Phase
PHASE1 / PHASE2
Sponsor
Phanes Therapeutics
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Peluntamig (PT217)
  • Carboplatin + Etoposide
  • Paclitaxel.
  • Atezolizumab
  • Lurbinectedin
  • Irinotecan (drug)
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Denver, Colorado, United States|39.73915,-104.9847
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • 18 years or older and able to sign informed consent and comply with the protocol.
  • Measurable disease as defined by RECIST v1.1 criteria for solid tumors.
  • NECs that have transformed from NSCLC are not eligible.
  • Part A: Patients with histologically or cytologically confirmed unresectable advanced or metastatic small cell lung cancer (SCLC), large cell neuro…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →